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ABSTRACT  
Aim: To compare the glycaemic outcomes of 2 glucose-lowering treatment strategies in 
vulnerable (moderately ill and/or frail) patients aged 65 years with type 2 diabetes 
whose individual HbA1c targets were not met with diet/exercise and/or oral 
antihyperglycaemic medications (OAMs). 
Methods: The primary endpoint of this study was a composite of achieving/maintaining 
individualised HbA1c targets without clinically significant hypoglycaemia (severe 
hypoglycaemia or repeated hypoglycaemia causing interruption of patients activities or 
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blood glucose <54 mg/dL). Strategy-A comprised glucose-dependent therapies (N=99) 
with a non-sulphonylurea OAM and a glucagon-like peptide-1 receptor agonist as the 
first injectable. Strategy-B comprised non-glucose-dependent therapies (N=93) with 
sulphonylurea as the preferred OAM and insulin glargine as the first injectable. 
Results: There was no significant difference between Strategies A and B in 
percentages of patients achieving the primary endpoint (64.5% vs 54.9%; P=0.190). 
Mean incidences (A vs B) of total (10.2% vs 53.8%), documented symptomatic (5.1% vs 
36.6%), and asymptomatic (8.2% vs 32.3%) hypoglycaemia were lower for Strategy-A 
(P<0.001 each). Proportions of patients achieving/maintaining HbA1c target (A, 63.3% 
vs B, 55.9%) were similar. 
Conclusions: Similar proportions of older, vulnerable aged 65 years patients with type 
2 diabetes achieved/maintained glycaemic treatment goals without clinically significant 
hypoglycaemia with Strategies A or B. However, Strategy-A resulted in lower risk of 
total, documented symptomatic, and asymptomatic hypoglycaemia. These results 
identify an approach of potential clinical benefit in this age group and will inform future 
clinical research in older patients with type 2 diabetes. 
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INTRODUCTION 
Diabetes global prevalence is ~20% in people aged 65 to 79 years [1], most have 
type 2 diabetes (T2D), and rates are increasing [2-4]. Such patients are often vulnerable 
because of comorbid conditions and/or frailty [5,6]. Lowering blood glucose (BG) is a 
mainstay of treatment, regardless of age and functional status [7,8]. In older patients, 
the main objective is to avoid/minimise symptoms and potential complications of 
hyperglycaemia [6,9]. Older individuals are also prone to hypoglycaemia [10], 
consequences of which can be severe [11]. 
Optimal management in this population is difficult to define, however, largely 
because patients with frailty and/or significant comorbidities are underrepresented in 
trials and, if included, functional status is typically not reported [8,9,12,13]. Therefore, it 
remains unclear whether the intensive glycaemic control benefits demonstrated in 
younger patients [9,14], can be achieved in such older patients. 
There is also uncertainty about appropriate glycaemic targets for each patient. 
When selecting individual targets, the relative importance of individual characteristics 
will vary depending on practitioner experience, patient characteristics and comorbidities, 
and specific clinical circumstances [15]. Various guidelines recommend individualised 
glycaemic targets aligned with functional status for people with T2D [7,16,17]; however, 
recommended targets have not been validated in clinical trials involving older 
populations. 
Sulphonylurea therapy continues to be commonly prescribed in monotherapy or 
in combination with other OAMs [18-20], and basal insulin continues to be 
recommended as first-line injectable therapy to people with T2D [7,16]. Despite the 
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importance of avoiding hypoglycaemia in older patients [6,9], these therapies are still 
considered reasonably safe options in this population as reflected by studies examining 
treatment patterns [19-21]. Sulfonylurea exerts its glucose-lowering action primarily 
through stimulation of insulin secretion [22]. This action does not depend on blood 
glucose levels and thus may cause excessive insulin secretion and trigger 
hypoglycaemia [23]. New classes of antihyperglycaemic medications (e.g., dipeptidyl-
peptidase-4 [DPP-4] inhibitors, thiazolidinediones, injectable glucagon-like peptide-1 
receptor agonists [GLP-1 RA] and sodium-glucose cotransporter-2 [SGLT-2] inhibitors), 
typically do not trigger excessive insulin secretion and do not increase the risk of 
hypoglycemia [7,24]. Hypersecretion of incretin hormones resulting in lowering blood 
glucose to hypoglycemic levels has been described in some pathophysiological states 
e.g. in patients with Long QT syndrome [25] or in patients after gastric by-pass surgery 
[26]. However in broad populations of people with T2D the risk of hypoglycemia with 
incretin-based therapies has been shown to be low [27]. 
In the present study, we evaluated effects of 2 antihyperglycaemic treatment 
strategies in vulnerable (moderately ill and/or frail) older patients (65 years) with 
suboptimally-controlled T2D. Strategy-A used oral and injectable therapies that do not 
stimulate insulin secretion when BG reaches normal/low values (a glucose-dependent 
mode of action). GLP-1 RA [27] was a preferred first-line injectable. Sulphonylurea 
therapy [22] and insulin were excluded. Strategy-B used treatments that exert their 
glucose-lowering effect irrespective of prevailing glycaemia; sulphonylurea [22] as 
preferred OAM and insulin as preferred first-line injectable therapy (non-glucose-
dependent agents). We tested the hypothesis that more patients in Strategy-A would 
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achieve better results (i.e. more patients reaching their individual glycaemic target 
without hypoglycaemia) than -in Strategy-B. 
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METHODS 
Study Design 
This randomised, multinational, open-label, inǦlabel, active-controlled, parallel-
group study involved moderately ill and/or frail older patients. The primary objective was 
to assess relative success of 2 treatment strategies in achieving/maintaining glycaemic 
control without clinically significant hypoglycaemia. The study, which was planned to 
continue for 72 weeks (Figure S1), was preceded by an internal pilot phase (described 
in this paper) that included ~20% of the planned full study population who were treated 
for 24 weeks. Once this number was reached, enrollment in the full study was paused 
and an interim analysis was conducted. Enrollment was to resume if interim results 
indicated feasibility of the full study. Interim results (unblinded efficacy and safety data) 
were evaluated by an internal Data Monitoring Committee (DMC). 
The study was conducted according to the ethical principles of the Declaration of 
Helsinki and Council for International Organisations of Medical Science International 
Ethical Guidelines, the International Conference on Harmonisation Good Clinical 
Practice Guidelines, and applicable laws and regulations. 
Eligibility Criteria 
Eligible patients (male or female) were 65 years with T2D, HbA1c >7.3% (56 
mmol/mol) and <10.9% (96 mmol/mol) and 0.4% higher than the upper limit of the 
individualised target range set at screening. Patients were assessed according to 
established frailty scales (Clinical Frailty Scale [CFS]), [28] and comorbidities (Total 
Illness Burden Index [TIBI]), [29] in older individuals, and were required to have a CFS 
score 4 and/or a TIBI score 5. Patients could enroll if before study entry they were 
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treated with diet and exercise (if metformin contraindicated) or for 3 months received 
OAMs, as monotherapy/dual combination: sulphonylurea (any dose); maximally 
tolerated/effective doses of metformin (1500 mg/day), DPP-4 inhibitor (any marketed 
dose), thiazolidinedione (30 mg/day of pioglitazone/4 mg/day of rosiglitazone), or 
acarbose (75 mg/day). 
Selection of Individualised HbA1c Target 
For each individual, treatment aimed at achieving and maintaining individualised, 
preset HbA1c target ranges, while avoiding hypoglycaemia. Individual HbA1c targets 
(7.5-7.9%, 7.0-7.4%, and <7%) were determined at screening. HbA1c targets were 
ultimately at investigator discretion, based on presence of comorbidities and 
complications, cognitive status, life expectancy, duration of diabetes, functional status, 
and hypoglycaemic risk, and were agreed between investigator and patient at 
screening. Guidelines for selection of individualised treatment targets are available 
online (Appendix S2). 
Treatment 
Investigators were provided general management rules and guidance for using 
study treatments according to locally-approved product labels; however, within a given 
strategy, choice of specific treatments and their combinations was at their discretion. 
Self-monitoring of BG was performed at the discretion of the investigator. Treatments 
were titrated throughout until maximally tolerated and/or approved doses or HbA1c 
target was reached. If maximally tolerated and/or approved doses were reached but 
individualised HbA1c targets were not met, next-line therapy was initiated by adding 
another treatment. 
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Marketed OAMs and injectable glucose-lowering treatments were used across 
different lines of treatment in each strategy, beginning with a single OAM and 
progressing to 3 OAMs, and first-line injectable therapy. 
Patients randomised to Strategy-A (Figure S2) were excluded from 
sulphonylurea and insulin therapy. If OAMs were not effective and injectable treatment 
was indicated, Strategy-A patients commenced available GLP-1 RA therapy (exenatide 
twice-daily, exenatide once-weekly, or liraglutide). Patients randomised to Strategy-B 
(Figure S3) were treated with glimepiride as part of any OAM treatment line 
(monotherapy, dual, or triple combination) and insulin glargine as first-line injectable 
treatment. If appropriate, investigators could start next-line therapy once the patient was 
receiving glimepiride 4 mg/day. Insulin glargine dosage was adjusted based on self-
monitored fasting BG (FBG) according to study titration algorithms (Appendix S3), with 
the aim of reaching HbA1c target without hypoglycaemia. Once injectable treatment 
was started, OAM could be continued in combination with GLP-1 RA or insulin at the 
same/lower dose or could be discontinued, at investigator discretion. 
Metformin, pioglitazone, DPP-4 inhibitors, and acarbose could be used in either 
strategy; other antihyperglycaemic medications, including SGLT-2 inhibitors, were 
excluded from both strategies. Some pre-study treatments were replaced at study entry: 
rosiglitazone was replaced with pioglitazone, and DPP-4 inhibitors other than linagliptin 
or sitagliptin, were replaced with either of these. For patients randomised to Strategy-B, 
sulphonylureas other than glimepiride, were replaced with this medication, while in 
Strategy-A, sulphonylurea was stopped and replaced with other OAMs. These and other 
treatments were continued throughout the study. 
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Outcome Measures 
The primary outcome was a composite of achieving and maintaining 
individualised HbA1c targets without clinically significant hypoglycaemia. This was 
defined as any one of the following: i) severe hypoglycaemia (signs and symptoms 
consistent with hypoglycaemia, requiring assistance of another person and associated 
with BG 70 mg/dL/prompt recovery after oral carbohydrate/glucagon/intravenous 
glucose); ii) within 1 month, 2 documented events of symptomatic hypoglycaemia 
(confirmed with BG ≤70 mg/dL) that forced the patient to interrupt what he/she was 
currently doing/or 2 nocturnal hypoglycaemic events (confirmed with BG ≤70 mg/dL) 
that woke the patient and forced him/her to act; iii) within 2 weeks, 2 events of 
asymptomatic documented hypoglycaemia (BG <54 mg/dL) detected by self-monitoring. 
Achievement of primary outcome and maintainence until study end was 
considered a treatment success. Conversely, treatment was considered a failure if any 
of the following occurred: i) individualised HbA1c treatment target not 
reached/maintained at 2 consecutive determinations starting from week-24 for patients 
with data beyond week-24, or not reached at week-24 for patients without data beyond 
week-24; ii) clinically significant hypoglycaemia; iii) HbA1c target not achieved at study 
discontinuation. 
Secondary efficacy outcomes included proportions of patients reaching treatment 
target at last available visit, proportions of patients requiring alternative treatment after 
glycaemic failure of first-line injectable therapy, and change from baseline to endpoint in 
HbA1c. 
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Safety assessments included incidence and rate of hypoglycaemia including 
severe and nocturnal hypoglycaemia, presence of diabetic kidney disease (DKD) 
(estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 or albumin-to-creatinine 
ratio >30 mg/g), progression of DKD (30% decrease in eGFR from baseline/increased 
albumin-to-creatinine ratio from 30 mg/g at baseline to >30300 mg/g post-baseline) 
[30,31], and incidence of adverse events. 
 
Statistical Analysis 
Demographic and baseline characteristics data were summarised using 
descriptive statistics. Categorical analyses were performed using Chi-squared or 
Fishers exact test. 
Logistic regression with treatment target, country, and baseline HbA1c as 
covariates was applied to the comparison between treatment strategies of proportions 
of patients achieving treatment success, and to proportions of patients reaching 
individualised HbA1c target at last available visit. Hypothesis testing was two-sided with 
an Į=0.05 significance level. 
HbA1c changes from baseline (randomisation) were analysed using a mixed-
model repeated measures approach that included treatment, baseline HbA1c, treatment 
target, country, prestudy OAM use, pre-study sulphonylurea use, and treatment-by-visit 
interaction as fixed effects. 
A pre-defined interim analysis was to be performed when ~142 patients 
completed 24 weeks of treatment. Conditional power (CP) was calculated to determine 
the feasibility of the full study and was defined according to prespecified protocol 
criteria. If the CP was promising (0.200.95), the study was continued and sample size 
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was increased to a maximum of 660 completed patients; if favourable (>0.95), the 
study was continued using the planned sample size of 500 completed patients; if 
unfavourable (<0.20), the study was terminated. 
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RESULTS 
Patients 
A total of 388 patients were enrolled/screened from February 2014 to October 
2015 at 40 study sites in 4 countries (Austria, Germany, UK, US [including Puerto 
Rico]), and 192 patients were entered/randomised to Strategy-A (N=99) and Strategy-B 
(N=93). Of these, 98 and 93 patients, respectively, were treated and included in the 
analysis (Figure 1). Baseline patient characteristics were generally similar between 
strategies (Table 1, Table S1). 
Study Treatment 
At final analysis patients had received treatment for a median duration of 49.0 
weeks (range 0.1-78.6 weeks), with the most frequent treatment modality being 3 OAMs 
in Strategy-A (32.7% of patients) and 2 OAMs in Strategy-B (40.9% of patients), both 
without injectable therapy (Table 2). More than 40% (Strategy-A) and ~20% (Strategy-
B) of patients started injectable (4th-line) therapy in combination with 1-3 OAMs. 
Predominant OAMs were metformin (83.7%), DPP-4 inhibitors (67.3%), and 
thiazolidinediones (pioglitazone, 60.2%) in Strategy- A, and glimepiride (95.7%), 
metformin (89.2%), and DPP-4 inhibitors (49.5%) in Strategy-B. 
Primary Outcome 
The primary outcome, was not significantly different between treatment strategies 
(A, 68.9% vs B, 65.9% of patients; P=0.666) at the pre-defined interim analysis. This 
lack of a difference between strategies in treatment success was apparent in each of its 
components: failure to achieve and maintain individualized glycaemic targets and 
similar percentages of patients with clinically significant hypoglycaemia in both 
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strategies. Further analysis yielded a CP of 0.05, indicating an unfavourable 
probability of demonstrating a difference between strategies in treatment success, even 
if the sample size was increased for the full study. On the basis of these results and 
recommendations from the DMC, the study was discontinued. Once the decision to stop 
the trial was made, patients were asked to come for their next scheduled study visit 
which was considered final. 
For the primary outcome at final analysis (Table 3), there was no significant 
difference between treatment strategies (A, 64.5% vs B, 54.9% of patients; P=0.190). 
Failure to achieve/maintain HbA1c target occurred in 36.7% of patients in Strategy-A 
and 44.1% in Strategy-B, and 34.7% and 38.7% of patients, respectively, did not 
achieve HbA1c target at study discontinuation. Clinically significant hypoglycaemia was 
reported in Strategy-B only (1.1% of patients). Patients in Strategy-A were more likely 
than those in Strategy- B to be receiving injectable therapy at HbA1c target failure (i.e. 
3 OAMs + 1st-line injectable; 21.4% vs 14. 0%) (Table 3). 
There were no significant differences between treatment strategies in proportions 
of patients reaching/maintaining HbA1c target at last visit, or in HbA1c change from 
baseline to endpoint (Table 3). 
Safety 
Incidences of total, documented symptomatic, and asymptomatic hypoglycaemic 
events were significantly lower in Strategy-A than in Strategy-B (10.2% vs 53.8%; 5.1% 
vs 36.6%; 8.2% vs 32.3%, respectively; P<0.001 for each), as were mean (SD) overall, 
documented symptomatic, and asymptomatic 30-day rates: 0.05 (0.23) vs 0.31 (0.91); 
0.03 (0.17) vs 0.22 (0.89); and 0.01 (0.09) vs 0.07 (0.15) events/patient/30 days, 
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respectively; P<0.001 for each). Differences between Strategies A and B in incidences 
of severe hypoglycaemia (0% vs 0%) and nocturnal hypoglycaemia (4.1% vs 10.8%) 
were not statistically significant. 
Proportions of patients with 1 treatment-emergent adverse event (TEAE) were 
similar for both strategies (A, 84.7%; B, 79.6%), while treatment-related TEAEs 
occurred more frequently in Strategy-A (27.6% vs 8.6%, P<0.001). The most frequent 
TEAEs (5% of patients in either strategy) are summarised in Table 4. The 
gastrointestinal TEAEs, diarrhoea (12.2% vs 6.5%) and nausea (7.1% vs 3.2%), were 
more common for Strategy-A. Falls resulting in TEAEs occurred in 9.2% and 9.7% of 
patients in Strategies A and B, respectively, but none were considered related to 
hypoglycaemia. 
Seven patients were discontinued due to an AE (A, n=5 [5.1%]; B, n=2 [2.2%]) 
but only 1 was considered related to treatment (BG increased [A]). Serious AEs 
occurred in 29 patients (A, n=15 [15.3%]; B, n=14 [15.1%]; P=0.961), including 2 deaths 
in Strategy-A (1 cerebrovascular accident; 1 acute myocardial infarction). None of these 
events were considered related to study treatment. 
There was no difference between strategies in proportions of patients with kidney 
disease at study endpoint (A, 39.8%; B, 45.2%; P=0.453), or in evidence of disease 
progression (A, 10.2%; B, 11.8%; P=0.720).  
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DISCUSSION 
A significant challenge in treating older patients with diabetes is achieving 
glucose targets without increased risk of hypoglycaemia. We report the results of the 
first study attempting to compare benefits and risks of treatment strategies available in a 
group representative of the older population. The study aimed at assessing whether a 
glucose dependent (Strategy-A) versus a non-glucose dependent (Strategy-B) 
antihyperglycaemic strategy may achieve better results in the primary composite 
endpoint of achieving and maintaining individualised glycaemic treatment goals without 
clinically significant hypoglycaemia in older, vulnerable patients with T2D. The novelty 
of this study is the primary endpoint, selected to comprise avoidance of both 
hyperglycaemia and hypoglycaemia. Other novel features include involvement of a well-
characterised (from a functional standpoint) older population who were frail and/or had 
comorbidities together with evaluation of treatment strategies across multiple lines of 
therapy and use of individualised glycaemic targets. 
Both strategies resulted in improved glycaemic control and clinically meaningful 
HbA1c reductions of ~1.1%. At endpoint, mean HbA1c was 7.2% in each cohort. 
Improved glucose control was achieved with no clinically significant hypoglycaemia and 
a significantly lower incidence of total, symptomatic, and asymptomatic hypoglycaemia 
in Strategy-A. However, it was evident from the interim results that Strategy-B confers a 
significantly greater hypoglycaemia risk pertaining to categories other than clinically 
significant episodes (ie, total, symptomatic, asymptomatic). 
Hypoglycaemic events are typically assigned different degrees of clinical 
importance, but information continues to emerge that suggests all such episodes may 
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be relevant. For example, recent data have shown increased risk of cardiac arrhythmias 
in association with both asymptomatic episodes with interstitial glucose levels <3.1 
mmol/L (severe episodes) [32] and nocturnal [33] hypoglycaemia. Given that any 
hypoglycaemic event may be considered clinically relevant, particularly in older, 
vulnerable populations, hindsight leads us to question whether our choice of primary 
endpoint was too stringent or restrictive in this study. Moreover, it is unlikely that, had 
any hypoglycaemic episode been used in the primary endpoint, the study would have 
been stopped on the basis of futility; however, this can only be confirmed in future 
studies designed to investigate benefits and risks of these 2 strategies in vulnerable, 
older patients. Given the frequent occurrence of asymptomatic hypoglycaemia in older 
patients, use of continuous glucose monitoring (CGM) in all patients in this study may 
have yielded some valuable data. Indeed, a subset of patients in this study were 
monitored by CGM and the results have been reported separately [34]. The major value 
of this study is in the lessons learned that can be applied to the conduct of future 
studies. As such, we examined this studys limitations. 
The first important point relates to the study population. Enrolled patients were 
generally younger and less frail than anticipated for Strategies A and B (mean CFS, 4.0 
and 4.1; mean TIBI, 3.9 and 3.7, respectively). Future trials may use more stringent 
enrollment criteria to ensure a greater proportion of ill/frail patients and/or include older 
patients, though enrolling very frail patients and/or very old patients in such a trial can 
be challenging. Furthermore, even in this population, differences between strategies in 
total, symptomatic, and asymptomatic hypoglycaemia were striking. Conversely, one 
may argue that enrolling a more vulnerable population, and thus setting less aggressive 
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HbA1c targets, may produce outcomes similar to those of the current study. The 
difference between number of enrolled/screened (388) and number of 
entered/randomised (192) patients also suggests that the study population may not be 
generalisable to a broader, more clinically relevant population. A second limitation, as 
discussed earlier, relates to choice of the hypoglycaemic component in the composite 
primary outcome. 
The definition of clinically significant hypoglycaemia applied to this study is to 
some extent, consistent with what we attempted to define as moderate hypoglycaemia, 
which is based on the concept that hypoglycaemic episodes cause significant disruption 
to lifestyle and are associated with both increased morbidity and mortality. This is a view 
increasingly shared by others. The ADA and EASD have recently published a position 
statement that argues that future clinical trials should include an additional 
hypoglycaemic outcome level of 3 mmol/l (54mg/dL) or below which they categorise as 
serious hypoglycaemia [35]. 
Hypoglycaemia (whichever definition is used) incidence is likely to be closely 
related to the glycaemic targets assigned to patients and aggressiveness in pursuing 
those targets. There has been a gradual move in recent years towards less aggressive 
HbA1c targets, particularly in older patients [7]. Although the lowest HbA1c target in this 
study (<7%) was chosen for approximately half the patients in each group, about one-
third of patients in each group did not achieve treatment success (the primary outcome) 
because of failure to achieve the target HbA1c. This suggests that despite glycaemic 
targets being agreed between clinician and patient, these were not aggressively 
pursued in many individuals. Stronger encouragement by study investigators to achieve 
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HbA1c target might have led to a higher success rate. However, clinicians reluctance to 
pursue relatively low HbA1c values may have been influenced by a number of factors 
including guideline recommendations [7,16,17], data showing better functional 
outcomes in older patients with higher HbA1c [36], and emergence of data showing a J-
shaped relationship between all-cause mortality and HbA1c in T2D, with a nadir at an 
HbA1c of ~7.5% [37]. This may have led physicians to be more cautious. However, 
notably, despite failure to show a difference between strategies in treatment success, 
both resulted in clinically meaningful HbA1c reductions of ~1.1%. In terms of study 
outcome, if glycaemic targets had been pursued more aggressively, it is likely that the 
hypoglycaemic component of the primary endpoint would have played a more 
substantial role in outcome, and a greater difference in treatment success rate 
between strategies might have been evident. 
The protocol-mandated treatment titration may also have contributed to failure to 
achieve glycaemic control. The protocol allowed a substantial degree of treatment 
discretion regarding titration and escalation of therapies, resulting in variations in 
individual interpretation of optimal treatment regimens and/or in primary outcome. 
Further, in hindsight, we feel that medication choices should have been better 
differentiated between the strategies (e.g., we permitted the use of DPP-4 inhibitors in 
both groups) and that guidance given to investigators in relation to drug choice and 
titration could have been clearer. The difference between groups in progression to use 
of injectable therapy (>40% in Strategy-A, ~20% in Strategy-B) may be related to the 
difference between GLP-1 RAs and insulin hypoglycaemia risk [38], resulting in greater 
willingness to use injectable therapy in Strategy-A. Further, the role of SGLT-2 
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inhibitors, which were not used in the current study because of limited experience with 
their use in older, vulnerable patients, remains to be seen in such a population. 
The planned treatment period of the interim analysis (24 weeks) is another factor 
that may have contributed to failure to achieve glycaemic control in some patients. 
Given the recommendation that antihyperglycaemic medication titration should be 
initiated at low doses in older patients and titrated slowly, allowing up to 3 months 
between changes in medication [16], it is possible that the minimum study duration (i.e., 
24 weeks) was not long enough for clinicians to achieve the desired degree of 
glycaemic control, though the median duration was 42 weeks. Notably, per the final 
protocol for the full study, 36 weeks was considered sufficient time to reach the HbA1c 
target, even for those patients requiring multiple dose adjustments and changes of 
therapy (i.e., additions of OAMs). 
In conclusion, when success is defined as a combination of glycaemic control 
and absence of clinically significant hypoglycaemia (as defined in this study), treatment 
strategies involving glucose-dependent and non-glucose-dependent antihyperglycaemic 
medications result in similar success rates in vulnerable older patients with T2D. 
However, total, documented symptomatic, and asymptomatic hypoglycaemia were 
significantly less frequent in Strategy-A, a finding that, upon reflection, is clinically 
relevant in a patient population in which hypoglycaemia can have serious implications. 
The results of this study will also inform future clinical research in older patients with 
T2D.  
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FIGURE LEGEND 
Figure 1. Patient flow chart of moderately ill and/or frail older patients (65 years) with 
suboptimally controlled type 2 diabetes mellitus included in the interim analysis (patients 
treated for 24 weeks).
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Table 1. Baseline patient characteristics 
 Strategy-A 
N=99 
Strategy-B 
N=93 
Male 56 (56.6) 59 (63.4) 
Age, years   
Mean ± SD 70.7 ± 5.3 70.7 ± 4.4 
Median (min, max) 70.0 (65, 91) 70.0 (65, 82) 
75 17 (17.2) 18 (19.4) 
Race   
Caucasian  92 (92.9) 81 (87.1) 
Black or African American 7 (7.1) 11 (11.8) 
American Indian or Alaska Native 0 (0.0) 1 (1.1) 
Ethnicity   
Hispanic or Latino 35 (35.4) 32 (34.4) 
Weight, kg 86.2 ± 17.2 88.5 ± 16.4 
BMI, kg/m2 31.0 ± 5.7 31.3 ± 4.8 
HbA1c, %   
Mean ± SD 8.4 ± 0.9 8.2 ± 0.8 
<8 42 (42.4) 41 (44.1) 
8 to <9 35 (35.4) 38 (40.9) 
9 to <10 15 (15.2) 12 (12.9) 
10 7 (7.1) 2 (2.2) 
HbA1c target, %   
<7 47 (47.5) 47 (50.5) 
7 to <7.5 39 (39.4) 36 (38.7) 
7.5 to <8 13 (13.1) 10 (10.8) 
FBG, mg/dL 174.6 ± 45.0 167.4 ± 43.2 
eGFR, mL/min/1.73 m2   
30 to <60 22 (22.2) 16 (17.6) 
60 to <90 51 (51.5) 51 (56.0) 
90 26 (26.3) 24 (26.4) 
Prior antidiabetic treatment   
Naïve 3 (3.0) 1 (1.1) 
1 OAM 38 (38.4) 40 (43.0) 
2 OAMs 50 (50.5) 44 (47.3) 
>2 OAMs 8 (8.1) 8 (8.6)  
Prior sulphonylurea use 51 (51.5) 38 (40.9) 
TIBI*    
Mean ± SD 3.9 ± 2.2 3.7 ± 2.5 
Total score 5 37 (37.8) 31 (33.3) 
CFS*   
Mean ± SD 4.0 ± 0.5 4.1 ± 0.6 
Total score 4 91 (92.9) 91 (97.8) 
TIBI score 5 or CFS score 4 97 (99.0) 93 (100) 
TIBI score 5 and CFS score 4 31 (31.6) 29 (31.2) 
TIBI score <5 and CFS score <4 1 (1.0) 0 
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BMI, body mass index; CFS, Clinical Frailty Scale; eGFR, estimated glomerular filtration rate; FBG, fasting blood 
glucose; HbA1c, glycated hemoglobin; OAM, oral antihyperglycaemic medication; SD, standard deviation; TIBI, 
Total Illness Burden Index. 
Data are presented as mean ± SD or n (%) unless otherwise indicated 
*n=98 for glucose-dependent strategy. 
NOTE: The distribution of patients by TIBI and CFS scores by treatment strategy is provided in Table S1 in the 
online supporting information.
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Table 2. Study treatment* 
 
Strategy-A 
N=98 
Strategy-B 
N=93 
 Treatment modalities   
1 OAM 2 (2.0) 2 (2.2) 
2 OAMs 23 (23.5) 38 (40.9) 
3 OAMs 32 (32.7) 30 (32.3) 
1 OAM + injectable 15 (15.3) 1 (1.1) 
2 OAMs + injectable 18 (18.4) 7 (7.5) 
3 OAMs + injectable 7 (7.1) 14 (15.1) 
Injectable only 1 (1.0) 1 (1.1) 
Study drug   
Biguanides: Metformin 82 (83.7) 83 (89.2) 
DPP-4 Inhibitors 66 (67.3) 46 (49.5) 
Sitagliptin 50 (51.0) 34 (36.6) 
Linagliptin 16 (16.3) 12 (12.9) 
SUs: Glimepiride 1 (1.0) 89 (95.7) 
TZDs: Pioglitazone 59 (60.2) 7 (7.5) 
GLP-1 RAs 40 (40.8) 0 
Liraglutide 17 (17.3) 0 
Exenatide QW 22 (22.4) 0 
Exenatide BID  1 (1.0) 0 
Insulin glargine 2 (2.0) 23 (24.7) 
Į Glucosidase inhibitors: acarbose 8 (8.2) 0 
BID, twice daily; DPP-4, dipeptidyl-peptidase-4; GLP-1 RAs, glucagon-like peptide-1 receptor 
agonists; OAM, oral antihyperglycaemic medication; QW, once weekly; SUs, sulphonylureas; 
TZDs, thiazolidinediones 
Data are presented as n (%) 
*Maximum line of therapy 
These patients (protocol violations) were included in the analysis as the small numbers in each 
strategy were not anticipated to impact the study results.  
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Table 3. Treatment outcomes 
 Strategy-A 
N=98 
Strategy-B 
N=93 
Relative success of treatment strategies    
Success*, n (%) 62 (63.3) 52 (55.9) 
Adjusted % (95% CI) 64.5 (54.4, 73.4) 54.9 (44.6, 64.9)  
Adjusted % (95% CI)/P value, A vs B strategy 9.5 (4.7,23.2)/0.190 
 Conditional power  0.58  
Failure, n (%) 36 (36.7) 41 (44.1) 
Reason for failure, n (%)   
Clinically significant hypoglycaemia 0 1 (1.1) 
HbA1c target not reached/maintained§  36 (36.7) 41 (44.1) 
Treatment at HbA1c target failure||, (n %)   
1 OAM 3 (3.1) 1 (1.1) 
2 OAMs 8 (8.2) 12 (12.9) 
3 OAMs 3 (3.1) 15 (16.1) 
3 OAMs + first-line injectable 21 (21.4) 13 (14.0) 
HbA1c target not achieved at study 
discontinuation 
34 (34.7) 36 (38.7) 
HbA1c target at last visit    
Success, n (%) 64 (65.3) 55 (59.1) 
Adjusted % (95% CI) 67.5 (57.3, 76.2) 57.8 (47.2, 67.7) 
Adjusted % (95% CI)/P value, A vs B strategy 9.7 (4.5,23.4)/0.182 
Failure, n (%) 34 (34.7) 38 (40.9) 
HbA1c from baseline to endpoint   
Baseline, mean % (SD) n=98, 8.4 (0.9) n=93, 8.2 (0.8) 
Endpoint, mean % (SD) n=96, 7.2 (1.3) n=92, 7.2 (0.8) 
Change from baseline to endpoint, LS mean % (SE) 1.17 (0.10) 1.05 (0.10) 
LS mean % (95% CI)/P value, A vs B -0.12 (0.40,0.16)/0.390 
CI, confidence interval; HbA1c, glycated hemoglobin; OAM, oral antihyperglycaemia medication; HbA1c, 
glycated hemoglobin; LS, least squareSD, standard deviation; SE, standard error 
*Treatment strategy was considered a success if HbA1c target was reached /maintained with no clinically 
significant hypoglycaemia. 
Treatment (Strategy-A vs Strategy-B) was considered Promising for a conditional power (CP) of 0.20-0.95, 
Favorable for a CP >0.95, and Unfavorable for a CP <0.20. 
Patients could have been counted in more than 1 category. 
§Individualised HbA1c treatment target was not reached/maintained upon 2 consecutive determinations starting 
from week 24 for patients with data beyond week 24, or not reached at week 24 for patients without data beyond 
week 24. 
||One patient in Strategy-A did not have a treatment record as this patient was discontinued for a protocol 
violation (week 4) but was included as a treatment failure due to unmet HbA1c target at the last available 
visit.  
Note: Adjusted proportions and P values were based on a logistic regression model with treatment target, 
country, and baseline HbA1c as covariates. 
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Table 4. Treatment-emergent adverse events (TEAEs; >5% in either arm)  
TEAE, n (%) Strategy-A 
N=98 
Strategy-B 
N=93 
Any TEAE 83 (84.7) 74 (79.6) 
Nasopharyngitis 10 (10.2) 16 (17.2) 
Back pain 9 (9.2) 11 (11.8) 
Diarrhoea 12 (12.2) 6 (6.5) 
Vitamin D deficiency 9 (9.2) 3 (3.2) 
Urinary tract infection 3 (3.1) 8 (8.6) 
Nausea 7 (7.1) 3 (3.2) 
Upper respiratory tract 
infection 
3 (3.1) 7 (7.5) 
Chikungunya virus infection 4 (4.1) 5 (5.4) 
Hypertension 5 (5.1) 4 (4.3) 
Headache 7 (7.1) 1 (1.1) 
Oedema 6 (6.1) 0 (0.0) 
Weight decreased 5 (5.1) 0 (0.0) 
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Figure 1 
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